From target mutation to testable shortlist
Candidate generation, biological filtering, structure and context evaluation, then explainable multi-objective ranking.
KritRNA is developing a coupled computational platform: one engine designs and ranks suppressor-tRNA candidates; the second models how each candidate perturbs the wider translation system. Selected candidates must then be tested experimentally.
The two engines are intended to exchange constraints. A sequence that looks viable in isolation may still fail when termination competition, transcript surveillance or cellular stress are considered.
Candidate generation, biological filtering, structure and context evaluation, then explainable multi-objective ranking.
A mechanistic network intended to connect translation dynamics, surveillance, stress signalling and protein output.
KritRNA’s intended defensibility is not one public algorithm or one database. It is the evolving combination of biological constraints, candidate-generation logic, assay-normalised evidence, mechanistic models and wet-lab feedback.
Rules defining viable search space without disclosing exact generation logic.
Coupled sequence, structure, charging, context, kinetics and safety filters.
Versioned candidate and assay records, including failures and uncertainty.
Experimental outcomes progressively reshape prioritisation and calibration.
Readthrough depends on timing and context. The model therefore needs more than a static tRNA structure score.
Model competition between suppressor-tRNA accommodation and eRF1/eRF3-mediated termination.
Estimate how sequence context and decoding behaviour affect residence time at the premature stop.
Consider the stop codon, the +4 nucleotide and surrounding sequence features that influence termination.
Assess whether a design is likely to preserve productive recognition by its intended aminoacyl-tRNA synthetase.
Represent transcript context that can influence nonsense-mediated decay and available message abundance.
Account for cellular stress, tRNA modification state, ribosome collisions and integrated-stress-response risk.
Readthrough measurements from different assays are related but not automatically commensurable. The platform is designed to preserve experimental context rather than pooling every number into one misleading target.
Keep experimental readouts tied to assay type, cell context, expression level and measurement method instead of treating every percentage as equivalent.
Combine sequence, structure, thermodynamic, evolutionary, kinetic and transcript-context features.
Use interpretable feature contributions so a shortlist can be challenged scientifically before it reaches the bench.
Use each wet-lab round to prioritise the next experiments with the highest expected information value.
Separate model confidence from biological promise and avoid presenting a score as evidence of therapeutic efficacy.
Preserve candidate history, assay provenance and versioned outcomes so the platform learns without erasing failed designs.

KritRNA is at an early, preclinical research stage. These pages describe a platform under active development, not a validated therapeutic product. Experimental validation remains the next major evidence gate.